Literature DB >> 12132540

Depression in palliative care: a systematic review. Part 2. Treatment.

Kelly Lan Ly1, Jayne Chidgey, Julia Addington-Hall, Matthew Hotopf.   

Abstract

OBJECTIVE: To summarize available literature containing data on the treatment of depression in palliative care patients.
METHODS: A systematic review was conducted using extensive electronic databases and hand searches. All randomized controlled trials (RCTs) of interventions for depression in patients with advanced disease were eligible.
RESULTS: Three RCTs assessed pharmacological treatments. Of these, two were placebo controlled and assessed mianserin and thioridazine. The third compared two antidepressants. There were no RCTs that specifically assessed psychotherapy for patients with depression.
CONCLUSION: There are too few adequate studies to draw clear conclusions about management of depression in this setting. The treatment of depression in patients with advanced disease must, for now, be informed by the larger body of evidence on effective treatments for depression in patients with either no physical illness or less severe medical conditions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12132540     DOI: 10.1191/0269216302pm570oa

Source DB:  PubMed          Journal:  Palliat Med        ISSN: 0269-2163            Impact factor:   4.762


  10 in total

1.  How family physicians address diagnosis and management of depression in palliative care patients.

Authors:  Franca Warmenhoven; Eric van Rijswijk; Elise van Hoogstraten; Karel van Spaendonck; Peter Lucassen; Judith Prins; Kris Vissers; Chris van Weel
Journal:  Ann Fam Med       Date:  2012 Jul-Aug       Impact factor: 5.166

2.  The important application of thioridazine in the endometrial cancer.

Authors:  Qiong Meng; Xiao Sun; Jing Wang; Yudong Wang; Lihua Wang
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

3.  Depressive disorder in the last phase of life in patients with cardiovascular disease, cancer, and COPD: data from a 20-year follow-up period in general practice.

Authors:  Franca Warmenhoven; Hans Bor; Peter Lucassen; Kris Vissers; Chris van Weel; Judith Prins; Henk Schers
Journal:  Br J Gen Pract       Date:  2013-05       Impact factor: 5.386

4.  Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells.

Authors:  Sokbom Kang; Seung Myung Dong; Boh-Ram Kim; Mi Sun Park; Barry Trink; Hyun-Jung Byun; Seung Bae Rho
Journal:  Apoptosis       Date:  2012-09       Impact factor: 4.677

Review 5.  Depression and end-of-life care for patients with cancer.

Authors:  Donald L Rosenstein
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

6.  Roles of dopamine receptors and their antagonist thioridazine in hepatoma metastasis.

Authors:  Meiling Lu; Jinghua Li; Zaili Luo; Shuai Zhang; Shaobo Xue; Kesheng Wang; Yan Shi; Cunzhen Zhang; Haiyang Chen; Zhong Li
Journal:  Onco Targets Ther       Date:  2015-06-22       Impact factor: 4.147

7.  Dopamine receptor antagonist thioridazine inhibits tumor growth in a murine breast cancer model.

Authors:  Tao Yin; Sisi He; Guobo Shen; Tinghong Ye; Fuchun Guo; Yongsheng Wang
Journal:  Mol Med Rep       Date:  2015-06-22       Impact factor: 2.952

8.  Thioridazine inhibits angiogenesis and tumor growth by targeting the VEGFR-2/PI3K/mTOR pathway in ovarian cancer xenografts.

Authors:  Mi Sun Park; Seung Myung Dong; Boh-Ram Kim; Seung Hee Seo; Sokbom Kang; Eun-Ju Lee; Seung-Hoon Lee; Seung Bae Rho
Journal:  Oncotarget       Date:  2014-07-15

9.  How should we manage information needs, family anxiety, depression, and breathlessness for those affected by advanced disease: development of a Clinical Decision Support Tool using a Delphi design.

Authors:  Liesbeth M van Vliet; Richard Harding; Claudia Bausewein; Sheila Payne; Irene J Higginson
Journal:  BMC Med       Date:  2015-10-13       Impact factor: 8.775

Review 10.  Repurposing Antipsychotics for Cancer Treatment.

Authors:  Nikolaos Vlachos; Marios Lampros; Spyridon Voulgaris; George A Alexiou
Journal:  Biomedicines       Date:  2021-11-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.